Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials

Christopher Em Griffiths; Marjolein de Bruin‐Weller; Mette Deleuran; Maria Concetta Fargnoli; D. Staumont‐Sallé; Chih-ho Hong; Jose Sánchez-Carazo; Peter Foley; Seong Jun Seo; Jérôme Msihid; Zhen Chen; Sonya Cyr; Ana B. Rossi

doi:10.1007/s13555-021-00558-0

Article2019

Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials

Andrew Alexis, Marta I. Rendon, Jonathan I. Silverberg, David M. Pariser, Benjamin Lockshin, Christopher Em Griffiths, Jamie Weisman, Andreas Wollenberg, Zhen Chen, John D. Davis, Meng Li, Laurent Eckert, Abhijit Gadkari, Brad Shumel, Ana B. Rossi, Neil M.H. Graham, Marius Ardeleanu

Article2019

Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials

Andrew Alexis, Marta I. Rendon, Jonathan I. Silverberg, David M. Pariser, Benjamin Lockshin, Christopher Em Griffiths, Jamie Weisman, Andreas Wollenberg, Zhen Chen, John D. Davis, Meng Li, Laurent Eckert, Abhijit Gadkari, Brad Shumel, Ana B. Rossi, Neil M.H. Graham, Marius Ardeleanu

Article2020

Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

Craig L. Leonardi, Kristian Reich, Peter Foley, Hideshi Torii, Sascha Gerdes, Lyn Guenther, Melinda Gooderham, Laura K. Ferris, Christopher Em Griffiths, Hany Elmaraghy, Heidi M. Crane, Himanshu J. Patel, Russel Burge, Gaia Gallo, David Shrom, Ann N. Leung, Chen‐Yen Lin, Kim Papp

Article2017

Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

Andrew Blauvelt, Kim Papp, Christopher Em Griffiths, L. Puig, Jamie Weisman, Yves Dutronc, Lisa Farmer Kerr, Dapo Ilo, Lotus Mallbris, Matthias Augustin

Article2017

Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies

Christopher Em Griffiths, Maurizio Fava, Andrew H. Miller, James Russell, Susan Ball, Wen Xu, Nayan Acharya, Mark Hyman Rapaport

Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials

Abstract

Discussion(0)

Related publications

Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials

Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials

Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies